Physician profile
Aaron Diodato
NPI 1396705844
$5,693.64
in general payments reported to CMS, 2019-2025
33 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $427 · 2021: $537 · 2022: $1,127 · 2023: $872 · 2024: $1,194 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224 · Education: $15.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.23 |
| Education | $15.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $744.19 | 2019-2025 | Farxiga, Lokelma, Lynparza |
| Otsuka America Pharmaceutical, INC. | $568.65 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $383.03 | 2022-2025 | |
| Amgen INC. | $345.68 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Calliditas Therapeutics US INC. | $299.49 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $298.30 | 2019-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $278.09 | 2021-2025 | Lupkynis |
| Kyowa Kirin, INC. | $269.79 | 2023-2025 | Crysvita |
| Vifor Pharma, INC. | $246.23 | 2020-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.45 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $217.02 | 2020-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $214.93 | 2024-2025 | |
| Ardelyx, INC. | $196.73 | 2023-2025 | Ibsrela |
| Biomerieux INC | $180.85 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $178.26 | 2020-2023 | Acthar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174.40 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $104.75 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $91.07 | 2021-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.71 | 2022-2024 | Jynarque |
| Ultragenyx Pharmaceutical INC. | $82.39 | 2021-2022 | |
| Nxstage Medical, INC. | $70.83 | 2019 | |
| Fresenius USA Marketing, INC. | $63.64 | 2019-2024 | Velphoro |
| Glaxosmithkline, LLC. | $63.06 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $47.39 | 2019 | |
| Pharmacosmos Therapeutics INC. | $44.26 | 2022-2025 | Monoferric |
| Amag Pharmaceuticals, INC. | $35.19 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $35.06 | 2021-2025 | Rayaldee |
| Cormedix INC. | $34.33 | 2025 | Defencath |
| Alnylam Pharmaceuticals INC. | $26.37 | 2023 | Givlaari |
| Lundbeck LLC | $19.04 | 2021 | |
| Lilly USA, LLC | $17.95 | 2025 | Zepbound |
| Akebia Therapeutics INC | $17.66 | 2024 | Vafseo, Auryxia |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Diodato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.